Neutral impactStocks

156% rally in one day! Why this drugmaker stock witnessed such skyrocketing jump on Wall Street

Economic Times 19 min ago·18 Nov 2026, 6:39 am

Sellas Life Sciences shares surged 156% after its experimental leukemia vaccine, galinpepimut-S (GPS), significantly extended survival in a late-stage trial. The treatment reduced death risk by 41%, with median survival reaching 24 months. The company plans FDA discussions, targeting an accelerated approval filing in 2027.

Key takeaways

  • Category: Stocks.

Why it matters

A routine update. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Economic Times.

More Stocks news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.